EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia

Soravis Osataphan iD, Maria Vamvini, Evan D Rosen, Lei Pei, Natanie Erlikh, Gurcharan Singh, Poojaben Dhorajiya, J Anthony Parker, Jonathan M Dreyfuss, Ahmed Rattani, Mary-Elizabeth Patti iD

New England Journal of Medicine · 2023

DOI: 10.1056/nejmc2307576 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Soravis Osataphan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Hypoglycemia, Insulinoma, Pancreatic Neoplasms, Insulin. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoglycemia is a life-threatening complication of malignant insulinoma that can be refractory to maximal medical therapy that targets the tumor and insulin secretion and action simultaneously.We report the successful use of RZ358, a novel human anti-insulin receptor monoclonal antibody, in a patient with metastatic insulinoma in whom severe, refractory maryelizabeth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoglycemiaInsulinomaPancreatic NeoplasmsInsulinInsulin AntagonistsHumansAntibodies

Substanzen

AntibodiesInsulinInsulin Antagonists

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA.
  • Joslin Diabetes Center, Boston, MA.
  • Joslin Diabetes Center, Boston, MA maryelizabeth.patti@joslin.harvard.edu.

ORCID-Profile: Soravis Osataphan, Mary-Elizabeth Patti

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Osataphan, S., Vamvini, M., Rosen, E. D., Pei, L., Erlikh, N., Singh, G., Dhorajiya, P., Parker, J. A., Dreyfuss, J. M., Rattani, A., & Patti, M. E. (2023). Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia. New England Journal of Medicine. https://doi.org/10.1056/nejmc2307576

Vancouver

Osataphan S, Vamvini M, Rosen ED, Pei L, Erlikh N, Singh G, et al. Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia. New England Journal of Medicine. 2023. doi:10.1056/nejmc2307576

BibTeX
@article{Osataphan2023,
  author = {Osataphan, Soravis and Vamvini, Maria and Rosen, Evan D and Pei, Lei and Erlikh, Natanie and Singh, Gurcharan and Dhorajiya, Poojaben and Parker, J Anthony and Dreyfuss, Jonathan M and Rattani, Ahmed and Patti, Mary-Elizabeth},
  title = {Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia},
  journal = {New England Journal of Medicine},
  year = {2023},
  doi = {10.1056/nejmc2307576}
}
Kostenlos starten →